I don't disagree that's in the shareholder's best interest. But Vivek and co have their own end game and it no doubt ends in their new positions at D&D. Most likely some cushy paid non-executive directorship or advisory role.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
